Wedbush Reiterates an 'Outperform' on Sunesis Pharmaceuticals (SNSS); Increased Confidence After Board Recommendation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Notable 52-Week Highs and Lows of the Day 09/11: (GE) (SNSS) (HOV) High; (EXC) (GERN) (COOL) Low
September 11, 2012 2:09 PM EDTThis report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:General Electric Co. (NYSE: GE) high of $21.69. GE is moving right along with broader markets today, looking to make it seven winning sessions out of the last 11.
Earlier, GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging... More
Unusual 11 Mid-Day Movers 09/11: (WSB) (SNSS) (CTIC) Higher; (NAVB) (GNOM) (CENT) Lower
September 11, 2012 12:56 PM EDTWSB Holdings, Inc. (Nasdaq: WSB) 82.9% HIGHER; Old Line Bancshares, Inc. (Nasdaq: OLBK) will acquire WSB Holdings for $6.12 per share in cash and stock, subject to adjustment.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) 35.8% HIGHER; will implement a one-time, 225-patient sample size increase to its Phase 3 VALOR trial of vosaroxin... More
Leerink Swann reiterates an 'Outperform' on Sunesis Pharmaceuticals (SNSS); Vosaroxin in the 'Zone'
September 11, 2012 10:59 AM EDTLeerink Swann reiterates an 'Outperform' on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) price target of $7.00.
Analyst, Irene Lau, said, "We believe many investors will be satisfied by this interim outcome which should drive further interest and investment in SNSS. We believe near... More
Pre-Open Movers 9/11: (WSM) (SNSS) (CASY) Higher; (NAVB) (PPO) (SQNM) Lower (more...)
September 11, 2012 9:31 AM EDTWSB Holdings, Inc.(NASDAQ: WSB) 91% HIGHER ; acquired by Old Line Bancshares (NASDAQ: OLBK).
Sunesis Pharma (NASDAQ: SNSS) 47% HIGHER ; to Boost Sample Size in Phase 3 VALOR of Vosaroxin in AML
Navidea Biopharmaceuticals, Inc (NASDAQ:... More
Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin
September 11, 2012 8:57 AM EDTCantor Fitzgerald reiterates a 'Buy' on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) price target raised to $8.00.
Analyst, Mara Goldstein, said, "Following a planned interim analysis of the VALOR study, Sunesis will expand the patient enrollment of the study by 225 patients. This news... More
Sunesis Pharma (SNSS) to Boost Sample Size in Phase 3 VALOR of Vosaroxin in AML
September 11, 2012 7:07 AM EDTSunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will implement a one-time, 225-patient sample size increase to its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML), bringing target enrollment to 675 patients. This is in response to the recommendation of the trial's independent Data and Safety Monitoring... More
